CTNM — Contineum Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $106.07m
- -$98.69m
Annual income statement for Contineum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 50 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 28.6 | 22.7 | 33.9 | 50.9 |
| Operating Profit | -28.6 | -22.7 | 16.1 | -50.9 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -29 | -24.3 | 23.2 | -42.3 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -29 | -24.3 | 22.7 | -42.3 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -29 | -24.3 | 22.7 | -42.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -29 | -24.3 | 22.7 | -42.3 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1.15 | -0.965 | 0.904 | -2.18 |